# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment...
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising...
Mizuho analyst Graig Suvannavejh maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price targe...
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion acro...
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. P...
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outloo...
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, st...